_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Visualise is an innovative consensus-driven medical education programme that was developed to deliver practical and relevant hands-on examples and discussion of decision making for disease control in the management of retinal diseases. The Visualise programme launched in 2019 and the content is ratified by expert consensus and opinion.

The aim of the Visualise programme is to:

  • help up-skill healthcare professionals in order to improve effective diagnosis, management and treatment of retinal diseases including nAMD and its clinical complications
  • provide access to expert opinions and discussions
  • provide case studies that represent practical and relevant real-life examples of patient management strategies for disease control in retinal diseases

Please contact your local MSL if you require more information on Visualise.

 

 

Differential diagnosis in nAMD

Professor Geeta Menon discusses a variety of different patient cases and what to look for when diagnosing nAMD. She also introduces and demonstrates the Moorfields platform.

 

Optimising nAMD service: in-clinic and beyond

In this video, Dawn Sim discusses how to deliver nAMD services effectively, from referral through to personalised patient treatment and home care.

 
 

Importance of anatomical efficacy for disease control in nAMD

An animation summarising the impact of nAMD on patients, appropriate assessment and diagnosis, and best practice guidance for optimal patient care.

 

Treating beyond the eye

A short animation providing advice for healthcare professionals on how to improve practices, experiences and understanding for patients living with nAMD.

 

 

AMD, age-related macular degeneration; MSL, medical science liaison; nAMD, neovascular age-related macular degeneration.

Rate this content: 
Average: 5 (3 votes)
UK | March 2022 | 143843-1
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]